01—Abstract
Summary
Summary of the 8-K filed July 17, 2025. Cited figures are marked; the original filing is the authoritative source.
Elevance Health (ELV) reported second quarter 2025 results on July 17, 2025, with operating revenue of $49.4 billiona, up 14.3% year over year, driven by higher Health Benefits premium yields, acquisitions, and Medicare Advantage growth.
However, profitability weakened sharply: the benefit expense ratio rose 260 basis points to 88.9% on elevated medical cost trend in Medicaid and ACA plans, operating gain fell 12.3% to $2.4 billionb, and GAAP diluted EPS dropped 21.6% to $7.72 (adjusted EPS $8.84, down 14.2%). Health Benefits operating margin compressed to 3.8% from 5.8%, while Carelon was a bright spot, with segment revenue up 36% and operating gain up 33%. Management revised its full-year 2025 outlook, now expecting GAAP diluted EPS of approximately $24.10 and adjusted diluted EPS of approximately $30.00.
Management attributed the revision to elevated cost trends in ACA and slower rate alignment in Medicaid, and reiterated a long-term target of at least 12% average annual adjusted EPS growth. Cash generation was solid, with year-to-date operating cash flow of $3.1 billionc (0.8x GAAP net income), and the company returned $2.0 billion to shareholders year to date through buybacks and dividends, with about $8.0 billion of repurchase authorization remaining.
The key investor takeaway is that the quarter reflects a cost-trend problem in the core Health Benefits business that offset strong top-line growth and Carelon expansion. Investors should focus on whether medical cost trends in Medicaid and ACA stabilize, the pace of Medicaid rate alignment, and the durability of the revised earnings guidance.
02—Key points
Key Highlights
- Operating revenue of $49.4B rose 14.3% YoY, driven by premium yield increases, acquisitions, and Medicare Advantage membership growth, partly offset by Medicaid attrition.
- Benefit expense ratio rose 260 bps to 88.9% on higher medical cost trend, primarily in Medicaid and ACA; Health Benefits operating margin fell to 3.8% from 5.8%.
- Q2 GAAP diluted EPS was $7.72 (down 21.6% YoY); adjusted diluted EPS was $8.84 (down 14.2% YoY).
- FY2025 outlook revised: GAAP diluted EPS of approximately $24.10 and adjusted diluted EPS of approximately $30.00, reflecting elevated ACA cost trends and slower Medicaid rate alignment.
- Carelon operating revenue rose 36% to $18.1B, and operating gain rose 33% to $0.9B, driven by acquisitions in home health and pharmacy and CarelonRx product growth.
- Operating expense ratio improved 160 bps to 10.1% (adjusted 10.0%), reflecting expense leverage and cost discipline.
- Returned $2.0B to shareholders year to date; Q2 repurchased $379M of stock and paid a $1.71 quarterly dividend, with about $8.0B of authorization remaining. Medical membership declined to 45.6M, down 212K from Q1.
03—Questions
Frequently Asked Questions
Why did Elevance's profitability decline in Q2 2025 even though revenue grew 14%?
Revenue growth was driven by higher premium yields, acquisitions, and Medicare Advantage growth, but medical costs rose faster. The benefit expense ratio increased 260 basis points to 88.9%, mainly from higher medical cost trend in Medicaid and ACA health plans. Operating gain fell 12.3% to $2.4 billion.
Why did Elevance lower its 2025 earnings guidance?
Management cited elevated cost trends across the ACA individual market and slower rate alignment in Medicaid. Full-year adjusted diluted EPS guidance was revised to approximately $30.00, and GAAP diluted EPS guidance was set at approximately $24.10.
How strong is Elevance's cash flow and balance sheet position?
Operating cash flow was $3.1 billion year to date, or 0.8 times GAAP net income, up $0.6 billion year over year. Parent company cash and investments were about $2.2 billion as of June 30, 2025. Long-term debt was roughly $28.2 billion plus $1.6 billion current portion, so leverage remains a consideration for investors.
Is the Carelon business offsetting pressure in Health Benefits?
Partly. Carelon operating revenue grew 36% to $18.1 billion, and operating gain rose 33% to $0.9 billion on acquisitions and CarelonRx growth. However, Health Benefits operating gain fell 27% to $1.6 billion, so Carelon's gains do not fully offset the core segment's margin compression.
Will Elevance continue returning capital to shareholders?
The company declared a third-quarter 2025 dividend of $1.71 per share, payable September 25, 2025, and had about $8.0 billion of share repurchase authorization remaining as of June 30, 2025. It returned $2.0 billion year to date, though the revised earnings outlook may influence the pace of future buybacks.
04—Continue